

October 29, 2026

The Manager
Listing Department
National Stock Exchange of India Limited
Exchange Plaza, 5th Floor
Plot No. C1, 'G' Block, Bandra-Kurla Complex
Bandra (East), Mumbai 400 051.

BSE Limited
Corporate Relationship Department
Floor
25, P.J. Towers
Dalal Street
Mumbai 400 001.

Symbol: RPGLIFE

Scrip code: 532983

Dear Sir/Madam,

Sub: Outcome of Board Meeting of the Company held on October 29, 2026.

Pursuant to the provisions of Regulations 30 of SEBI (Listing Obligations & Disclosure Requirements) Regulations, 2015 and such other rules and regulations, as may be applicable, this is to inform you that the Board of Directors ('Board') of the Company at its meeting held today, which commenced at 03:00 PM (IST) and concluded at 06:50 PM (IST), *inter-alia*, unanimously approved/consented to/ took on record, the following:

A. Unaudited Financial Results

Unaudited Financial Results (Standalone and Consolidated) of the Company, for the quarter and half ended September 30, 2026, which are enclosed herewith, together with the respective Limited Review Report(s) issued by the Statutory Auditors of the Company.

B. Revised Policy on Related Party Transactions

The amended Policy on Related Party Transactions will be available on the website of the Company www.rpglifesciences.com.

Information pursuant to Regulation 30 of SEBI (Listing Obligations & Disclosure Requirements) Regulations, 2015, as amended, read with relevant SEBI Circular(s) are enclosed herewith. The above information will also be available on the website of the Company www.rpglifesciences.com.

The trading window for dealing in securities of the Company, shall open post 48 hours after declaration of the aforesaid Financial Results of the Company.

Kindly take the same on record.

Thanking you,

Yours faithfully,
For RPG Life Sciences Limited

RAJESH RAMESH SHIRAMBEKAR
Digitally signed by RAJESH RAMESH SHIRAMBEKAR
Date: 2026.10.29 21:27:12
+05'30'

Rajesh Shirambekar
Head – Legal & Company Secretary
Encl.- as above

Independent Auditor's Review Report on the Quarterly and Year to Date Unaudited Standalone Financial Results of the Company Pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended**Review Report to
The Board of Directors
RPG Life Sciences Limited**

1. We have reviewed the accompanying statement of unaudited standalone financial results of RPG Life Sciences Limited (the "Company") for the quarter ended September 30, 2026 and year to date April 1, 2026 to September 30, 2026 (the "Statement") attached herewith, being submitted by the Company pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended (the "Listing Regulations").
2. The Company's Management is responsible for the preparation of the Statement in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34, (Ind AS 34) "Interim Financial Reporting" prescribed under Section 133 of the Companies Act, 2013 as amended, read with relevant rules issued thereunder and other accounting principles generally accepted in India and in compliance with Regulation 33 of the Listing Regulations. The Statement has been approved by the Company's Board of Directors. Our responsibility is to express a conclusion on the Statement based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410, "Review of Interim Financial Information Performed by the Independent Auditor of the Entity" issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the Statement is free of material misstatement. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.
4. Based on our review conducted as nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in the aforesaid Indian Accounting Standards ('Ind AS') specified under Section 133 of the Companies Act, 2013 as amended, read with relevant rules issued thereunder and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of the Listing Regulations, including the manner in which it is to be disclosed, or that it contains any material misstatement.

For S R B C & CO LLP

Chartered Accountants

ICAI Firm registration number: 324982E/E300003

per Aruna Kumaraswamy
Partner

Membership No.: 219350

UDIN: 26219350HVRJV5679

Place: Mumbai

Date: October 29, 2026




Independent Auditor's Review Report on the Quarterly and Year to Date Unaudited Standalone Financial Results of the Company Pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended**Review Report to
The Board of Directors
RPG Life Sciences Limited**

1. We have reviewed the accompanying statement of unaudited standalone financial results of RPG Life Sciences Limited (the "Company") for the quarter ended September 30, 2026 and year to date April 1, 2026 to September 30, 2026 (the "Statement") attached herewith, being submitted by the Company pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended (the "Listing Regulations").
2. The Company's Management is responsible for the preparation of the Statement in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34, (Ind AS 34) "Interim Financial Reporting" prescribed under Section 133 of the Companies Act, 2013 as amended, read with relevant rules issued thereunder and other accounting principles generally accepted in India and in compliance with Regulation 33 of the Listing Regulations. The Statement has been approved by the Company's Board of Directors. Our responsibility is to express a conclusion on the Statement based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410, "Review of Interim Financial Information Performed by the Independent Auditor of the Entity" issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the Statement is free of material misstatement. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.
4. Based on our review conducted as nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in the aforesaid Indian Accounting Standards ('Ind AS') specified under Section 133 of the Companies Act, 2013 as amended, read with relevant rules issued thereunder and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of the Listing Regulations, including the manner in which it is to be disclosed, or that it contains any material misstatement.

For S R B C & CO LLP

Chartered Accountants

ICAI Firm registration number: 324982E/E300003

per Aruna Kumaraswamy
Partner

Membership No.: 219350

UDIN: 26219350 HVRJV 05679

Place: Mumbai

Date: October 29, 2026




Independent Auditor's Review Report on the Quarterly and Year to Date Unaudited Standalone Financial Results of the Company Pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended**Review Report to
The Board of Directors
RPG Life Sciences Limited**

1. We have reviewed the accompanying statement of unaudited standalone financial results of RPG Life Sciences Limited (the "Company") for the quarter ended September 30, 2026 and year to date April 1, 2026 to September 30, 2026 (the "Statement") attached herewith, being submitted by the Company pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended (the "Listing Regulations").
2. The Company's Management is responsible for the preparation of the Statement in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34, (Ind AS 34) "Interim Financial Reporting" prescribed under Section 133 of the Companies Act, 2013 as amended, read with relevant rules issued thereunder and other accounting principles generally accepted in India and in compliance with Regulation 33 of the Listing Regulations. The Statement has been approved by the Company's Board of Directors. Our responsibility is to express a conclusion on the Statement based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410, "Review of Interim Financial Information Performed by the Independent Auditor of the Entity" issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the Statement is free of material misstatement. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.
4. Based on our review conducted as nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in the aforesaid Indian Accounting Standards ('Ind AS') specified under Section 133 of the Companies Act, 2013 as amended, read with relevant rules issued thereunder and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of the Listing Regulations, including the manner in which it is to be disclosed, or that it contains any material misstatement.

For S R B C & CO LLP

Chartered Accountants

ICAI Firm registration number: 324982E/E300003

**per Aruna Kumaraswamy**
Partner

Membership No.: 219350

UDIN: 26219350 HVRJVB5679

Place: Mumbai

Date: October 29, 2026



RPG LIFE SCIENCES LIMITED

Regd. Office: RPG House, 463, Dr. Annie Besant Road, Worli, Mumbai 400 030

STATEMENT OF UNAUDITED STANDALONE FINANCIAL RESULTS FOR THE QUARTER AND SIX MONTHS ENDED SEPTEMBER 30, 2026

Particulars	Quarter ended			Six months ended		(Rs. in Lakhs)
	30-09-2026	30-06-2026	30-09-2025	30-09-2026	30-09-2025	Year ended
	Unaudited	Unaudited	Unaudited	Unaudited	Unaudited	Audited
1 Revenue from Operations	19,339	19,569	18,168	38,908	35,060	70,752
2 Other Income (Refer note 3(a))	377	416	454	793	977	2,554
3 Total Income (1+2)	19,716	19,985	18,622	39,701	36,037	73,306
4 Expenses						
(a) Cost of Materials Consumed	2,369	3,768	3,272	6,137	6,476	13,598
(b) Purchases of Stock-in-Trade	4,083	3,953	3,878	8,035	7,184	13,810
Changes in Inventories of Finished Goods, Work-in-Progress						
(c) and Stock-in-Trade	576	(906)	(492)	(330)	(1,000)	(2,199)
(d) Employee Benefits Expense	3,961	3,776	3,616	7,737	6,986	14,148
(e) Finance Costs	78	63	12	141	25	89
(f) Depreciation and Amortisation Expense	556	590	522	1,146	1,036	2,148
(g) Other Expenses	5,085	4,620	3,991	9,705	7,964	16,682
Total Expenses	16,708	15,864	14,799	32,572	28,671	58,276
5 Profit before exceptional items and tax (3-4)	3,008	4,121	3,823	7,129	7,366	15,030
6 Exceptional items (net) (Refer Note 3)	-	-	1,122	-	1,122	390
7 Profit before tax	3,008	4,121	4,945	7,129	8,488	15,420
8 Income tax expenses						
a. Current Tax	863	1,076	1,156	1,939	2,063	3,475
b. Deferred Tax	(184)	(12)	104	(196)	111	428
Total tax expenses	679	1,064	1,260	1,743	2,174	3,903
9 Profit for the period (7-8)	2,329	3,057	3,685	5,386	6,314	11,517
9 Profit for the period (7-8)	2,329	3,057	3,685	5,386	6,314	11,517
10 Other Comprehensive Income						
(i) Items that will not be reclassified to Profit or Loss	(20)	(20)	(3)	(40)	(5)	(86)
(ii) Income tax relating to items that will not be reclassified to Profit or Loss	5	5	1	10	2	22
Other Comprehensive Income / (Loss) Net of Tax	(15)	(15)	(2)	(30)	(3)	(64)
11 Total Comprehensive Income for the period (9+10)	2,314	3,042	3,683	5,356	6,311	11,453
12 Paid-up Equity Share Capital (Face Value Rs. 8/- each)	1,323	1,323	1,323	1,323	1,323	1,323
13 Other Equity						59,214
14 Earnings per Share (of Rs. 8/- each) (not annualised for the quarter):						
(a) Basic (in Rs.)	14.08	18.49	22.28	32.57	38.18	69.64
(b) Diluted (in Rs.)	14.08	18.49	22.28	32.57	38.18	69.64

SIGNED FOR IDENTIFICATION
BY
Ak
SRBC & CO LLP
MUMBAI



Statement of Standalone Assets and Liabilities

(Rs. in Lakhs)

Particulars	As at September 30, 2026	As at March 31, 2026
	(Unaudited)	(Audited)
ASSETS		
Non-current assets		
Property, plant and equipment (Including Right of use assets)	15,865	19,170
Capital work-in-progress	2,029	2,002
Other intangible assets	469	484
Intangible assets under development	327	327
Financial assets		
i. Investments	10,298	3,579
ii. Loans	-	14
iii. Other financial assets	48	43
Current Tax asset (Net)	579	526
Other non-current assets	533	700
Total non-current assets	30,148	26,845
Current assets		
Inventories	12,014	12,384
Financial assets		
i. Investments	6,402	8,390
ii. Trade receivables	13,118	11,668
iii. Cash and cash equivalents	10,180	11,568
iv. Bank balances other than (iii) above	942	4,110
v. Other financial assets	372	929
Other current assets	4,362	3,420
Total current assets	47,390	52,469
Total assets	77,538	79,314
EQUITY AND LIABILITIES		
Equity		
Equity share capital	1,323	1,323
Other equity	60,601	59,214
Total equity	61,924	60,537
Liabilities		
Non-current liabilities		
Financial liabilities		
i. Borrowings	-	1,333
ii. Lease liabilities	412	-
iii. Other financial liabilities	344	344
Provisions	739	741
Deferred tax liabilities (Net)	100	306
Total non-current liabilities	1,595	2,724
Current liabilities		
Financial liabilities		
i. Borrowings	-	667
i. Trade payables		
(a) total outstanding dues of micro enterprises and small enterprises	469	510
(b) total outstanding dues of creditors other than micro enterprises and small enterprises	9,357	9,211
ii. Other financial liabilities	1,200	2,044
Provisions	1,942	2,911
Other current liabilities	578	586
Current tax liabilities (Net)	473	124
Total current liabilities	14,019	16,053
Total liabilities	15,614	18,777
Total equity and liabilities	77,538	79,314

SIGNED FOR IDENTIFICATION

BY

AK

SRBC & CO LLP

AK

Unaudited Standalone Statement of cash flows for the six months ended September 30, 2026

(Rs. in Lakhs)

	Particulars	For the period ended September 30, 2026	For the period ended September 30, 2025
		Unaudited	Unaudited
A	Cash Flow from operating activities		
	Profit before income tax	7,129	8,488
	Adjustments for		
	Add/(Less) :		
	Depreciation and amortisation expenses	1,146	1,036
	Loss on account of fire incident / (Insurance proceeds), net	-	(1,122)
	Finance costs	141	25
	Loss on disposal of property, plant and equipment	10	-
	Unrealised exchange rate difference	26	(42)
	Provision for Doubtful Debts and Advances (Net)	56	(58)
	Less:		
	Interest received	(498)	(493)
	Gain on sale of investments	(224)	(330)
	Lease Rental income / expense	(25)	-
	Net fair value gain on financial assets mandatorily measured at fair value through profit or loss	(13)	(82)
	Provisions no longer required and written back	(1)	-
		7,747	7,422
	Working capital adjustments:		
	(Increase) in trade receivables	(1,532)	(3,093)
	Decrease in financial assets - Loans	9	1
	(Increase) / Decrease in other financial assets	(27)	(77)
	Decrease / (Increase) in other current assets	(1,109)	(1,546)
	Decrease / (Increase) in inventories	(2,259)	(1,399)
	(Decrease) / Increase in trade payables	1,275	1,842
	Increase / (Decrease) in lease liabilities	412	-
	(Decrease) / Increase in other financial liabilities	(521)	(380)
	Increase / (Decrease) in provisions	(299)	110
	Increase / (Decrease) in other current liabilities	210	62
	Cash generated from operations	3,906	2,942
	Income taxes paid	(1,597)	(1,815)
	Net cash inflow from operating activities	2,308	1,127
B	Cash flow from investing activities		
	Acquisition of property, plant and equipment and Intangible assets	(3,316)	(3,197)
	Interim payment received from insurance claim	750	960
	Movement in Other bank balances (Net)	3,168	(19)
	Sub-leasing Income from RPGAP	300	-
	Investment in Mutual fund	-	(1,000)
	Receipt from Sale of Mutual fund	2,224	4,830
	Investment in subsidiary	(6,569)	-
	Payment to acquire other non current investment	(150)	493
	Consideration received against Business Transfer to Subsidiary	3,353	-
	Interest received	498	-
	Net cash inflow/(outflow) from investing activities	258	2,067
C	Cash flow from financing activities		
	Proceeds from long term borrowings	500	-
	Proceeds from/ (Repayment of) long term borrowings	(328)	-
	Interest paid	(141)	(25)
	Repayment of principal portion of lease liability	(18)	-
	Dividend paid	(3,969)	(3,969)
	Net cash (outflow) from financing activities	(3,956)	(3,994)
	Net (decrease)/increase in cash and cash equivalents	(1,388)	(800)
	Add: Cash and cash equivalents at the beginning of the financial period	11,568	2,870
	Cash and cash equivalents at the end of the period	10,180	2,070

SIGNED FOR IDENTIFICATION

BY

AK

ML

Notes:

1. The above unaudited standalone financial results of the Company have been reviewed and recommended by the Audit Committee and have been approved by the Board of Directors at their respective meeting held on October 29, 2026

2. The Company operates in only one reportable business segment i.e. Pharmaceuticals.

3. Exceptional items:

Exceptional Income / (Expenses)	Quarter ended			Six months ended		Year ended
	30-09-2026	30-06-2026	30-09-2025	30-09-2026	30-09-2025	31-03-2026
	Unaudited	Unaudited	Unaudited	Unaudited	Unaudited	Audited
Net impact of Insurance claim on loss arising on account of fire incident - Refer note 3(a)	-	-	-	-	-	2,475
Impact of New Labour Codes - Refer note 3(b)	-	-	-	-	-	(1,169)
Impairment of Intangible Assets Under Development (IAUD) - Refer note 3(c)	-	-	-	-	-	(916)
Gain / (Loss) on account of fire incident	-	-	1,122	-	1,122	-
Total exceptional items - Income	-	-	1,122	-	1,122	390

3(a) During the year ended March 31, 2026, the Company received full settlement of the insurance claim relating to the fire incident at its Navi Mumbai API plant which occurred in January 2025. The settlement resulted in a net income of Rs. 2,475 lakhs which was recognized as Exceptional income in the respective quarters during FY26 when such claim proceeds were received. The Company had also recognized Rs. 791 lakhs received towards compensation for business interruption losses as Other income during the quarter ended March 31, 2026.

3(b) During the year ended March 31, 2026, the Company recognised an exceptional expense of Rs. 1,169 lakhs towards the impact of the New Labour Codes notified effective November 22, 2025, primarily arising from the change in wage definition. The Company continues to monitor further regulatory developments and will account for any additional impact, if required.

3(c) Exceptional items for the quarter and year ended March 31, 2026 includes write-off of an intangible asset under development. Based on management's annual assessment of impairment, no future economic benefits were expected to arise from the project. Accordingly, the accumulated costs incurred up to that date were written off and recognised as an exceptional item.

4. The Company entered into a Business Transfer Agreement ("BTA") on July 29, 2026, for transfer of its Active Pharmaceutical Ingredients ("API") Business to RPG Active Pharma Limited ("RPGAP"), a wholly owned subsidiary of the Company, as a going concern on a slump sale basis, for a consideration of Rs 3,355 lakhs. The transaction was consummated on August 15, 2026 ("Closing Date"). Accordingly, the financial results for the quarter and six months ended September 30, 2026 reflect the impact of the aforesaid transaction and, therefore, are not strictly comparable with those of the corresponding periods in the previous year.

5. During the quarter, pursuant to an Investment and Shareholders' Agreement ("IA") entered into amongst the Company, RPG Active Pharma Limited ("RPGAP"), India Life Sciences Fund IV Domestic ("ILSF") and Vistaject Fund ("VJF"), ILSF and VJF invested an aggregate amount of Rs 24,330 lakhs in RPGAP by way of subscription to equity shares and Compulsorily Convertible Preference Shares ("CCPS") allotted on September 9, 2026. Based on the contractual terms of the instrument and in accordance with the requirements of accounting standards, the CCPS have been classified as a financial liability in these financial results. Following the investment, the Company continues to exercise control over RPGAP. Accordingly, RPGAP continues to be consolidated as a subsidiary in the Company's consolidated financial results.

6. During the quarter, RPG Active Pharma Limited ("RPGAP"), a subsidiary of the Company

a) acquired the Active Pharmaceutical Ingredients ("API") and intermediates businesses of Raghava Life Sciences Private Limited ("RLSPL") as a going concern on a slump sale basis for a consideration of upto Rs 14,381 lakhs. The acquisition became effective on September 16, 2026. A portion of the purchase consideration is subject to hold back in accordance with the terms of the Business Transfer Agreement, and

b) acquired the entire equity share capital of Actis Generics Private Limited ("Actis") pursuant to a Share Purchase Agreement for a consideration of upto Rs 8,783 lakhs, with effect from September 24, 2026, consequent to which Actis became a wholly owned subsidiary of RPGAP and a subsidiary of the Company. A portion of the purchase consideration is subject to hold back in accordance with the terms of the Share Purchase Agreement.

The aforesaid acquisitions have been accounted in the consolidated financial results in accordance with Ind AS 103, Business Combinations, from their respective acquisition dates. The purchase price allocations ("PPA") are provisional pending completion of the valuation of the identifiable assets acquired and liabilities assumed including Goodwill and other intangible assets. Accordingly, the final allocations may differ from those considered in these consolidated financial results.

The consolidated financial results for the quarter and six months ended September 30, 2026 include the financial performance of the respective acquired businesses from their acquisition dates and, accordingly, are not strictly comparable with the corresponding previous periods.

Consequent to the acquisition of the business, the Board of Directors of RPGAP approved a Scheme of Amalgamation of Actis with RPGAP under Sections 230 to 232 and other applicable provisions of the Companies Act, 2013. The Scheme is subject to receipt of necessary approvals from the jurisdictional bench of the National Company Law Tribunal, shareholders of RPGAP, and such other persons and authorities, as may be required.

Place: Mumbai
Date: October 29, 2026



For RPG Life Sciences Limited

Ashok Nair
Ashok Nair
Managing Director
DIN: 07906710

Independent Auditor's Review Report on the Quarterly and Year to Date Unaudited Consolidated Financial Results of the Company Pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended

**Review Report to
The Board of Directors
RPG Life Sciences Limited**

1. We have reviewed the accompanying Statement of Unaudited Consolidated Financial Results of RPG Life Sciences Limited (the "Holding Company") and its subsidiaries (the Holding Company and its subsidiaries together referred to as "the Group") for the quarter ended September 30, 2026 and year to date from April 1, 2026 to September 30, 2026 (the "Statement") attached herewith, being submitted by the Holding Company pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended (the "Listing Regulations").
2. The Holding Company's Management is responsible for the preparation of the Statement in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34, (Ind AS 34) "Interim Financial Reporting" prescribed under Section 133 of the Companies Act, 2013 as amended, read with relevant rules issued thereunder and other accounting principles generally accepted in India and in compliance with Regulation 33 of the Listing Regulations. The Statement has been approved by the Holding Company's Board of Directors. Our responsibility is to express a conclusion on the Statement based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410, "Review of Interim Financial Information Performed by the Independent Auditor of the Entity" issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the Statement is free of material misstatement. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

We also performed procedures in accordance with the Master Circular issued by the Securities and Exchange Board of India under Regulation 33(8) of the Listing Regulations, to the extent applicable.

4. The Statement includes the results of following entities:
 - i. RPG Active Pharma Limited
 - ii. Actis Generics Private Limited
5. Based on our review conducted and procedures performed as stated in paragraph 3 and based on the consideration of the review reports of other auditors referred to in paragraph 6 below, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with recognition and measurement principles laid down in the aforesaid Indian Accounting Standards ('Ind AS') specified under Section 133 of the Companies Act, 2013, as amended, read with relevant rules issued thereunder and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of the Listing Regulations, including the manner in which it is to be disclosed, or that it contains any material misstatement.



S R B C & CO LLP

Chartered Accountants

6. The accompanying Statement includes the unaudited interim financial results and other unaudited financial information, in respect of:

- 1 subsidiary, whose unaudited interim financial results and other unaudited financial information include total assets of Rs. 10,829 lakhs as at September 30, 2026, total revenues of Rs 49 lakhs, total net loss after tax of Rs. 88 lakhs and total comprehensive income of Rs. 88 lakhs for the period from September 24, 2026 to September 30, 2026 and net cash inflows of Rs. 439 lakhs for the period from September 24, 2026 to September 30, 2026, as considered in the Statement whose unaudited interim financial results and other unaudited financial information which have been reviewed by their independent auditor.


The independent auditor's reports on interim financial results and other unaudited financial information of these entity have been furnished to us by the Management and our conclusion on the Statement, in so far as it relates to the amounts and disclosures in respect of these subsidiary is based solely on the report of such auditor and procedures performed by us as stated in paragraph 3 above.

Our conclusion on the Statement in respect of matters stated in para 6 above is not modified with respect to our reliance on the work done and the reports of the other auditor and the financial results certified by the Management.

For S R B C & CO LLP

Chartered Accountants

ICAI Firm registration number: 324982E/E300003



per Aruna Kumaraswamy

Partner

Membership No.: 219350

UDIN: 26219350LDS4026325

Place: Mumbai

Date: October 29, 2026



RPG LIFE SCIENCES LIMITED						
Regd. Office: RPG House, 463, Dr. Annie Besant Road, Worli, Mumbai 400 030						
STATEMENT OF UNAUDITED CONSOLIDATED FINANCIAL RESULTS FOR THE QUARTER AND SIX MONTHS ENDED SEPTEMBER 30, 2026						
Particulars	Quarter ended			Six months ended		(Rs. in Lakhs)
	30-09-2026	30-06-2026	30-09-2025	30-09-2026	30-09-2025	31-03-2026
	Unaudited	Unaudited	Unaudited	Unaudited	Unaudited	Audited
1 Revenue from Operations	21,164	19,569	18,168	40,733	35,060	70,752
2 Other Income (Refer note 3(a))	426	416	454	842	977	2,554
3 Total Income (1+2)	21,590	19,985	18,622	41,575	36,037	73,306
4 Expenses						
(a) Cost of Materials Consumed	2,410	3,768	3,272	6,178	6,476	13,598
(b) Purchases of Stock-in-Trade	5,872	3,953	3,878	9,825	7,184	13,810
Changes in Inventories of Finished Goods, Work-in-Progress						
(c) and Stock-in-Trade	(1,068)	(906)	(492)	(1,974)	(1,000)	(2,199)
(d) Employee Benefits Expense	4,409	3,776	3,616	8,185	6,986	14,148
(e) Finance Costs	84	63	12	147	25	89
(f) Depreciation and Amortisation Expense	680	590	522	1,270	1,036	2,148
(g) Other Expenses	5,499	4,620	3,991	10,119	7,964	16,682
Total Expenses	17,886	15,863	14,799	33,750	28,671	58,276
5 Profit before exceptional items and tax (3-4)	3,704	4,122	3,823	7,825	7,366	15,030
6 Exceptional items (net) (Refer Note 3)	-	-	1,122	-	1,122	390
7 Profit before tax	3,704	4,122	4,945	7,825	8,488	15,420
8 Income tax expenses						
a. Current Tax	866	1,076	1,156	1,942	2,063	3,475
b. Deferred Tax	16	(12)	104	4	111	428
Total tax expenses	882	1,064	1,260	1,946	2,174	3,903
9 Profit for the period (7-8)	2,822	3,058	3,685	5,879	6,314	11,517
10 Other Comprehensive Income						
(i) Items that will not be reclassified to Profit or Loss	(20)	(20)	(3)	(40)	(5)	(86)
(ii) Income tax relating to items that will not be reclassified to Profit or Loss	5	5	1	10	2	22
Other Comprehensive Income / (Loss) Net of Tax	(15)	(15)	(2)	(30)	(3)	(64)
11 Total Comprehensive Income for the period (9+10)	2,807	3,043	3,683	5,849	6,311	11,453
12 Profit for the period						
Attributable to:						
Owners of the parent	2,660	3,058	3,685	5,717	6,314	11,517
Non-Controlling Interest	162	-	-	162	-	-
13 Other Comprehensive Income						
Attributable to:						
Owners of the parent	(15)	(15)	(2)	(30)	(3)	(64)
Non-Controlling Interest	-	-	-	-	-	-
14 Total Comprehensive Income for the period (9+10)						
Attributable to:						
Owners of the parent	2,645	3,043	3,683	5,687	6,311	11,453
Non-Controlling Interest	162	-	-	162	-	-
15 Paid-up Equity Share Capital (Face Value Rs. 8/- each)	1,323	1,323	1,323	1,323	1,323	1,323
16 Other Equity						59,214
17 Earnings per Share (of Rs. 8/- each) (not annualised for the quarter):						
(a) Basic (in Rs.)	17.07	18.49	22.28	35.55	38.18	69.64
(b) Diluted (in Rs.)	17.07	18.49	22.28	35.55	38.18	69.64

SIGNED FOR IDENTIFICATION

BY

S R B C & CO LLP
MUMBAI

An **RPG** Company

Statement of Consolidated Assets and Liabilities

(Rs. in Lakhs)

Particulars	As at September 30, 2026 (Unaudited)	As at March 31, 2026 (Audited)
ASSETS		
Non-current assets		
Property, plant and equipment (Including Right of use assets)	35,052	19,170
Capital work-in-progress	2,044	2,002
Goodwill	675	-
Other intangible assets	4,868	484
Intangible assets under development	327	327
Financial assets		
i. Investments	251	3,579
ii. Loans	18	14
iii. Other financial assets	155	43
Deferred tax assets (Net)	-	-
Current Tax asset (Net)	704	526
Deferred tax assets (Net)	-	-
Other non-current assets	538	700
Total non-current assets	44,633	26,845
Current assets		
Inventories	17,339	12,384
Financial assets		
i. Investments	16,229	8,390
ii. Trade receivables	14,138	11,668
iii. Cash and cash equivalents	11,052	11,568
iv. Bank balances other than (iii) above	1,942	4,110
v. Other financial assets	119	929
Other current assets	6,188	3,420
Total current assets	67,007	52,469
Total assets	1,11,640	79,314
EQUITY AND LIABILITIES		
Equity		
Equity share capital	1,323	1,323
Other equity	67,398	59,214
Equity Attributable to Equity Holders of Parent	68,721	60,537
Non-Controlling Interest	17,925	-
Total equity	86,646	60,537
Liabilities		
Non-current liabilities		
Financial liabilities		
i. Borrowings	60	1,333
ii. Lease liabilities	417	-
ii. Other financial liabilities	344	344
Provisions	741	741
Deferred tax liabilities (Net)	509	306
Total non-current liabilities	2,072	2,724
Current liabilities		
Financial liabilities		
i. Borrowings	2,167	667
i. Trade payables		
(a) total outstanding dues of micro enterprises and small enterprises	795	510
(b) total outstanding dues of creditors other than micro enterprises and small enterprises	9,809	9,211
ii. Other financial liabilities	5,722	2,044
Provisions	980	2,911
Other current liabilities	2,800	586
Current tax liabilities (Net)	648	124
Total current liabilities	22,922	16,053
Total liabilities	24,994	18,777
Total equity and liabilities	1,11,640	79,314

SIGNED FOR IDENTIFICATION
BY 

SRBC & CO LLP
MUMBAI



An  RPG Company

Unaudited Consolidated Statement of cash flows for the six months ended September 30, 2026

(Rs. in Lakhs)

	Particulars	For the period ended September 30, 2026	For the period ended September 30, 2025
		Unaudited	Unaudited
A	Cash Flow from operating activities		
	Profit before income tax	7,825	8,488
	Adjustments for		
	Add/(Less) :		
	Depreciation and amortisation expenses	1,270	1,036
	Loss on account of fire incident / (Insurance proceeds), net	-	(1,122)
	Finance costs	147	25
	Loss on disposal of property, plant and equipment	10	-
	Unrealised exchange rate difference	26	(42)
	Provision for Doubtful Debts and Advances (Net)	56	(58)
	Less:		
	Interest received	(589)	(493)
	Gain on sale of investments	-	(330)
	Rental Income	(224)	-
	Provisions no longer required and written back	(1)	-
	Net fair value gain on financial assets mandatorily measured at fair value through profit or loss	(52)	(82)
		8,468	7,422
	Working capital adjustments:		
	(Increase) in trade receivables	(3,383)	(3,093)
	(Increase) / Decrease in financial assets (non-current)	645	(77)
	Decrease in financial assets - Loans	-	1
	(Increase) / Decrease in other non-current assets	(1,077)	(1,546)
	(Increase) / Decrease in inventories	(2,684)	(1,399)
	(Decrease) / Increase in trade payables	786	1,842
	Increase / (Decrease) in lease liabilities	-	-
	(Decrease) / Increase in other financial liabilities	(177)	(380)
	Increase / (Decrease) in provisions	(446)	110
	Increase / (Decrease) in other current liabilities	573	62
	Cash generated from operations	2,705	2,942
	Income taxes paid	(1,656)	(1,815)
	Net cash inflow from operating activities	1,049	1,127
B	Cash flow from investing activities		
	Acquisition of property, plant and equipment and Intangible assets	(3,334)	(3,197)
	Insurance claim received	750	960
	Movement in Other bank balances (Net)	2,168	(19)
	Investment in Mutual Funds	(9,826)	(1,000)
	Receipt from Sale of Mutual fund	2,263	4,830
	Consideration for acquisition of subsidiary (net of cash acquired)	(7,835)	-
	Consideration for acquisition of Business	(10,366)	-
	Interest received	589	-
	Payment to acquire other non current investment	(150)	493
	Net cash inflow/(outflow) from investing activities	(25,742)	2,067
C	Cash flow from financing activities		
	Proceeds from short term borrowings	500	-
	Proceeds from Issue of Equity Shares	24,273	-
	Proceeds from Issue of Preference Shares	60	(25)
	Repayment of principal portion of lease liability	(18)	-
	Dividend paid	(3,969)	(3,969)
	Interest paid	(147)	-
	Net cash (outflow) from financing activities	20,699	(3,994)
	Net (decrease)/increase in cash and cash equivalents	(3,995)	(800)
	Add: Cash and cash equivalents at the beginning of the financial period	15,046	2,870
	Cash and cash equivalents at the end of the period	11,052	2,070

SIGNED FOR IDENTIFICATION
BY
AK
SRBG & CO LLP



An **RPG** Company

Notes:

- The above unaudited consolidated financial results of the Group have been reviewed and recommended by the Audit Committee and have been approved by the Board of Directors at their respective meeting held on October 29, 2026
- The Group operates in only one reportable business segment i.e. Pharmaceuticals
- Exceptional items:

Exceptional Income / (Expenses)	Quarter ended			Six months ended		Year ended
	30-09-2026	30-06-2026	30-09-2025	30-09-2026	30-09-2025	31-03-2026
	Unaudited	Unaudited	Unaudited	Unaudited	Unaudited	Audited
Net impact of Insurance claim on loss arising on account of fire incident - Refer note 3(a)	-	-	-	-	-	2,475
Impact of New Labour Codes - Refer note 3(b)	-	-	-	-	-	(1,169)
Impairment of Intangible Assets Under Development (IAUD) - Refer note 3(c)	-	-	-	-	-	(916)
Gain / (Loss) on account of fire incident	-	-	1,122	-	1,122	-
Total exceptional items - Income	-	-	1,122	-	1,122	390


- During the year ended March 31, 2026, the Group received full settlement of the insurance claim relating to the fire incident at its Navi Mumbai API plant which occurred in January 2025. The settlement resulted in a net income of Rs. 2,475 lakhs which was recognized as Exceptional income in the respective quarters during FY26 when such claim proceeds were received. The Group had also recognized Rs. 791 lakhs received towards compensation for business interruption losses as Other income during the quarter ended March 31, 2026
 - During the year ended March 31, 2026, the Group recognised an exceptional expense of Rs. 1,169 lakhs towards the impact of the New Labour Codes notified effective November 22, 2025, primarily arising from the change in wage definition. The Company continues to monitor further regulatory developments and will account for any additional impact, if required
 - Exceptional items for the quarter and year ended March 31, 2026 includes write-off of an intangible asset under development. Based on management's annual assessment of impairment, no future economic benefits were expected to arise from the project. Accordingly, the accumulated costs incurred up to that date were written off and recognised as an exceptional item.
- During the quarter, pursuant to an Investment and Shareholders' Agreement ("IA") entered into amongst the Company, RPG Active Pharma Limited ("RPGAP"), India Life Sciences Fund IV Domestic ("ILSF") and Vistajet Fund ("VJF"), ILSF and VJF invested an aggregate amount of Rs. 24,330 lakhs in RPGAP by way of subscription to equity shares and Compulsorily Convertible Preference Shares ("CCPS") allotted on September 9, 2026. Based on the contractual terms of the instrument and in accordance with the requirements of accounting standards, the CCPS have been classified as a financial liability in these financial results. Following the investment, the Company continues to exercise control over RPGAP. Accordingly, RPGAP continues to be consolidated as a subsidiary in the Company's consolidated financial results
 - During the quarter, RPG Active Pharma Limited ("RPGAP"), a subsidiary of the Company:
 - acquired the Active Pharmaceutical Ingredients ("API") and intermediates businesses of Raghava Life Sciences Private Limited ("RLSPL") as a going concern on a slump sale basis for a consideration of upto Rs. 14,381 lakhs. The acquisition became effective on September 16, 2026. A portion of the purchase consideration is subject to hold back in accordance with the terms of the Business Transfer Agreement, and

b) acquired the entire equity share capital of Actis Generics Private Limited ("Actis") pursuant to a Share Purchase Agreement for a consideration of upto Rs. 8,783 lakhs, with effect from September 24, 2026, consequent to which Actis became a wholly owned subsidiary of RPGAP and a subsidiary of the Company. A portion of the purchase consideration is subject to hold back in accordance with the terms of the Share Purchase Agreement


The aforesaid acquisitions have been accounted in the consolidated financial results in accordance with Ind AS 103, Business Combinations, from their respective acquisition dates. The purchase price allocations ("PPA") are provisional pending completion of the valuation of the identifiable assets acquired and liabilities assumed including Goodwill and other Intangible assets. Accordingly, the final allocations may differ from those considered in these consolidated financial results.

The consolidated financial results for the quarter and six months ended September 30, 2026 include the financial performance of the respective acquired businesses from their acquisition dates and, accordingly, are not strictly comparable with the corresponding previous periods.

Consequent to the acquisition of the business, the Board of Directors of RPGAP approved a Scheme of Amalgamation of Actis with RPGAP under Sections 230 to 232 and other applicable provisions of the Companies Act, 2013. The Scheme is subject to receipt of necessary approvals from the jurisdictional bench of the National Company Law Tribunal, shareholders of RPGAP, and such other persons and authorities, as may be required.



For RPG Life Sciences Limited


Ashok Nair
Managing Director
DIN: 07906710

Place: Mumbai
Date: October 29, 2026